 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Sylentis Preps to Move Glaucoma Drug into Phase II Next Year
July 05, 2012
Sylentis Preps to Move Glaucoma Drug into Phase II Next Year
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sylentis Picks up Option to Alnylam RNAi IP
November 17, 2011 / Gene Silencing News - Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners
April 1, 2010 / Gene Silencing News - Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September
August 20, 2009 / Gene Silencing News - Spain's Sylentis Looks to Move siRNA-Based Glaucoma Drug into Phase I This Year
February 19, 2009 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Sylentis, Quark, NIH, and More
June 14, 2012 / Gene Silencing News